SAB Biotherapeutics, Inc.
SABS
$3.70
-$0.05-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.78M | -398.30K | 13.27M | 18.74M | -37.06M |
| Total Depreciation and Amortization | 3.12M | 3.06M | 3.08M | 3.10M | 3.30M |
| Total Amortization of Deferred Charges | 261.10K | 261.10K | 261.10K | -- | -- |
| Total Other Non-Cash Items | -40.03M | -47.36M | -57.71M | -61.12M | 757.40K |
| Change in Net Operating Assets | -4.51M | -6.81M | -3.69M | 1.75M | 2.22M |
| Cash from Operations | -53.94M | -51.25M | -44.78M | -37.53M | -30.77M |
| Capital Expenditure | -3.50M | -1.92M | -933.20K | -55.40K | -155.70K |
| Sale of Property, Plant, and Equipment | 3.00K | 2.70K | 1.00K | 1.00K | 1.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -198.61M | -190.11M | -120.77M | -110.61M | 18.20M |
| Cash from Investing | -202.11M | -192.02M | -121.71M | -110.67M | 18.05M |
| Total Debt Issued | -- | -- | -- | 516.00K | 516.00K |
| Total Debt Repaid | -148.70K | -284.20K | -418.70K | -656.10K | -1.27M |
| Issuance of Common Stock | 261.10M | 258.69M | 168.73M | 168.73M | 100.00 |
| Repurchase of Common Stock | -18.20K | -13.80K | -11.30K | -31.90K | -27.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -800.00 | -800.00 | -800.00 | 0.00 | -25.00K |
| Cash from Financing | 260.93M | 258.39M | 168.30M | 168.56M | -805.10K |
| Foreign Exchange rate Adjustments | -313.40K | -241.20K | -213.40K | -104.20K | -19.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.57M | 14.88M | 1.60M | 20.25M | -13.55M |